Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2022.874053 Oncology Correction Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma Che Li 1 † Paliogiannis Panagiotis 2 † Cigliano Antonio 3 Pilo Maria G. 2 Chen Xin 1 * Calvisi Diego F. 2 * 1 Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, San Francisco, CA, United States 2 Department of Medical, Surgical and Experimental Medicine, University of Sassari, Sassari, Italy 3 Institut für Pathologie, Universität Regensburg, Regensburg, Germany

Edited and reviewed by: Carlos Pérez-Plasencia, National Autonomous University of Mexico, Mexico

*Correspondence: Xin Chen, xin.chen@ucsf.edu; Diego F. Calvisi, calvisid@uniss.it

†These authors have contributed equally to this work

This article was submitted to Cancer Metabolism, a section of the journal Frontiers in Oncology

 12 04 2022 2022 12 874053 11 02 2022 24 03 2022 Copyright © 2022 Che, Paliogiannis, Cigliano, Pilo, Chen and Calvisi 2022 Che, Paliogiannis, Cigliano, Pilo, Chen and Calvisi

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma By Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X and Calvisi DF (2019). Front. Oncol. 9:1412. doi: 10.3389/fonc.2019.01412 hepatocellular carcinoma de novo lipogenesis FASN tumor metabolism precision medicine

In the original article, there was a mistake in Figure 3 as published. Specifically the structure of Orlistat was incorrect. The corrected Figure 3 appears below.

Chemical structures of the main FASN inhibitors tested in preclinical and clinical studies.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.